You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Claims for Patent: 11,452,692

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,452,692

Title:	Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
Abstract:	Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Inventor(s):	Aimesther BETANCOURT, Bruce Rehlaender, Roch Thibert
Assignee:	Karuna Therapeutics Inc
Application Number:	US17/649,826
Patent Claims:	1. A method of treating a disorder ameliorated by activating muscarinic receptors in a patient in need thereof, the method comprising administering between 100 mg and 125 mg xanomeline and/or a salt thereof and between 20 mg and 30 mg trospium salt to the patient twice daily; wherein the xanomeline and/or a salt thereof and trospium salt are administered as a pharmaceutical composition comprising a plurality of xanomeline beads having a core comprising the xanomeline or a salt thereof and optionally a coating, and a plurality of trospium beads having a core comprising the trospium salt and optionally a coating; and wherein the pharmaceutical composition is a capsule containing the plurality of xanomeline beads and the plurality of trospium beads. 2. The method of claim 1, wherein the disorder is chosen from schizophrenia, Alzheimer's disease, Parkinson's disease, depression, movement disorders, pain, drug addiction, tauopathy, and synucleinopathy. 3. The method of claim 1, wherein the disorder is schizophrenia. 4. The method of claim 1, wherein the administration is oral. 5. The method of claim 1, wherein the patient is treated for at least 7 days. 6. The method of claim 1, wherein the xanomeline and/or a salt thereof is xanomeline tartrate. 7. The method of claim 1, wherein the trospium salt is trospium chloride. 8. The method of claim 1, wherein the xanomeline and/or a salt thereof is xanomeline tartrate and the trospium salt is trospium chloride. 9. A method of treating schizophrenia in a patient in need thereof, the method comprising orally administering between 100 mg and 125 mg xanomeline tartrate and between 20 mg and 30 mg trospium chloride to the patient twice daily; wherein the xanomeline and/or a salt thereof and trospium salt are administered as a pharmaceutical composition comprising a plurality of xanomeline beads having a core comprising the xanomeline or a salt thereof and optionally a coating, and a plurality of trospium beads having a core comprising the trospium salt and optionally a coating. 10. The method of claim 9, wherein the patient is treated for at least 7 days. 11. The method of claim 1, wherein the size of the xanomeline beads is between 0.425 mm and 1.18 mm. 12. The method of claim 11, wherein the size of the xanomeline beads is between 0.6 mm and 0.85 mm. 13. The method of claim 1, wherein the size of the trospium beads is between 0.425 mm and 1.18 mm. 14. The method of claim 13, wherein the size of the trospium beads is between 0.6 mm and 0.85 mm. 15. The method of claim 9, wherein the size of the xanomeline beads is between 0.425 mm and 1.18 mm. 16. The method of claim 15, wherein the size of the xanomeline beads is between 0.6 mm and 0.85 mm. 17. The method of claim 9, wherein the size of the trospium beads is between 0.425 mm and 1.18 mm. 18. The method of claim 17, wherein the size of the trospium beads is between 0.6 mm and 0.85 mm.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.